Cited by 215Protease and Inhibitor MechanismsAcute Ischemic Stroke ManagementNeuroinflammation and Neurodegeneration Mechanisms

Multiphasic roles for matrix metalloproteinases after stroke

ROSELL, A, LO, E·2008·Current Opinion in Pharmacology

Abstract

Matrix metalloproteinases (MMPs) comprise a family of zinc endopeptidases that play major roles in the physiology and pathology of the mammalian central nervous system (CNS). These proteinases are evolutionarily conserved as modulators of extracellular matrix during CNS development. After acute tissue injury such as that which occurs after stroke, MMPs become dysregulated and subsequently mediate acute neurovascular disruption and parenchymal destruction. Data from gene knockout models and pharmacologic experiments suggest that MMPs may be attractive therapeutic targets for stroke. However, emerging data now also suggest that some aspects of MMP activity during the delayed neuroinflammatory response may contribute to remodelling and stroke recovery. Ultimately, a more nuanced approach to modifying the MMP response after stroke may be needed in order to optimize inhibition during acute stages of injury without interfering with beneficial endogenous mechanisms of neurovascular remodelling.

Integrity signals

Registry

Crossref · 10.1016/j.coph.2007.12.001

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
ROSELL, A., & LO, E.
Affiliations
Harvard University (US)
Corresponding author
  • ROSELL, A
  • LO, E
Venue
Current Opinion in Pharmacology
Publisher
Elsevier BV
Published
2008-02
Volume
8
Issue
1
Pages
82-89
ISSN
1471-4892 (ISSN-L)
OpenAlex
W2010817955
Cited by
215
References
62
Citations by year
2026: 2 · 2025: 5 · 2024: 4 · 2023: 5 · 2022: 7 · 2021: 11 · 2020: 11 · 2019: 11 · 2018: 9 · 2017: 12 · 2016: 20 · 2015: 15 · 2014: 13 · 2013: 21 · 2012: 21
FWCI
5.35
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
  • Health Sciences › Medicine › Epidemiology › Acute Ischemic Stroke Management
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
matrix metalloproteinases, stroke, extracellular matrix, neuroinflammation, matrix metalloproteinase inhibition, stroke recovery, therapeutic target
MeSH terms
Animals, Brain Ischemia, Humans, Neuronal Plasticity, Protease Inhibitors, Biomarkers, Stroke, Matrix Metalloproteinases, Matrix Metalloproteinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review